Jon P. Fryzek – Co-Founder, CEO
Dr. Fryzek, PhD, has 20 years of experience in the pharmaceutical industry and private consulting firms. He has conducted epidemiologic studies of cancer, connective tissue diseases, neurological diseases, infectious diseases, chronic renal failure, and medical devices. He has led numerous occupational studies, including studies of aerospace workers, automotive workers, diaper manufacturers, welders, motion picture film processing workers, and chemical manufacturers. His environmental studies involved examining the risk associated with DDT and other pesticides for pancreatic cancer patients, as well as the risk of environmental chromium associated with cancer. In support of Drug Development and Drug Safety, he has performed studies elucidating the natural history of various diseases, including descriptive incidence studies, “real-world” disease treatment pattern studies, and co-morbidity assessments. Dr. Fryzek has over 150 peer-reviewed manuscripts, book chapters, and scientific meeting abstracts. He has published in the New England Journal of Medicine, the Annals of Internal Medicine, the Journal of the National Cancer Institute, and the Journal of Occupational and Environment Medicine, among others, and is a scientific reviewer for a number of journals, including the American Journal of Epidemiology, Cancer Epidemiology, Biomarkers and Prevention, and the International Journal of Cancer. Dr. Fryzek is currently Adjunct Professor, University of Pittsburgh School of Public Health and Visiting Professor in the Department of Clinical Epidemiology, Aarhus University, Aarhus, Denmark.
Email Jon Fryzek
Dr. Fryzek’s CV August 2018
David H. Garabrant – Co-Founder, President
Dr. Garabrant, MD, MPH has over 30 years of experience in the design and conduct of epidemiological studies, litigation support, and independent research. He is board certified in Internal Medicine, Preventive Medicine, and Occupational Medicine. His research has focused on the long-term health effects of chemicals and pharmaceutical agents and devices. Specific topics include studies of exposure pathways for environmental dioxin contamination, meta-analyses of occupational risks related to motor vehicle mechanics and brake mechanics, cohort mortality studies, and case-control studies of pancreas, colorectal cancer, and head and neck cancer. Dr. Garabrant has over 350 research articles, book chapters, and abstracts related to these areas. He has published in many scientific journals including Occupational and Environmental Medicine, the Journal of the National Cancer Institute, Cancer Research and the Journal of Neurotoxicology. In addition, he was appointed to membership on the Safety and Occupational Health Study Section of the National Institutes of Health (NIH) in 1992 and served on that Study Section until 1996, having been appointed by Secretary of HHS Donna Shalala as Chair for the 1995-96 year. In 2007, he was awarded the Research Excellence Award from the University of Michigan Risk Center for his work on the health effects of dioxins. He is Emeritus Professor of Occupational Medicine and Epidemiology at the University of Michigan.
Email David Garabrant